-
Mashup Score: 0What Is the Link Between Tumor Features, CAR-T Response in MCL? | Blood Cancers Today - 3 hour(s) ago
Molecular features typically associated with inferior outcomes did not significantly affect survival or CAR-T response in patients with relapsed or refractory MCL.
Source: bloodcancerstoday.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1The OncoAlert Newsletter is NOW OUT Click to Register - 3 hour(s) ago
The OncoAlert Newsletter is now out for June 23-29, 2023
Source: www.OncoAlert360.comCategories: General Medicine News, Onc News and JournalsTweet-
RT @BenWestphalen: Out today 💥 The new @OncoAlert 🚨 #newsletter - if you don’t want to miss out: register at https://t.co/AxMKHsMAQC 🌐
-
-
Mashup Score: 1Acral Melanoma Survivor Warns: Know What to Look For - 7 hour(s) ago
Dorothy was shocked when diagnosed with acral melanoma, a rare, dangerous skin cancer. Now, she wants to educate people on what to look for.
Source: www.skincancer.orgCategories: General Medicine News, Onc News and JournalsTweet-
You'd never expect to get biopsied and diagnosed with a rare, dangerous skin cancer at the podiatrist. But that’s exactly what happened to Dorothy Overstreet. Now, she wants to educate people about acral lentiginous melanoma (ALM) and how to detect it. https://t.co/GwMrA94SYy https://t.co/ImOr8jRdJw
-
-
Mashup Score: 1The OncoAlert Newsletter is NOW OUT Click to Register - 7 hour(s) ago
The OncoAlert Newsletter is now out for June 23-29, 2023
Source: www.OncoAlert360.comCategories: General Medicine News, Onc News and JournalsTweet-
RT @BenWestphalen: Out today 💥 The new @OncoAlert 🚨 #newsletter - if you don’t want to miss out: register at https://t.co/AxMKHsMAQC 🌐
-
-
Mashup Score: 3The dual BCL-2 and BCL-XL inhibitor AZD4320 acts on-target and synergizes with MCL-1 inhibition in B-cell precursor ALL - 7 hour(s) ago
TO THE EDITOR:
Source: ashpublications.orgCategories: General Medicine News, Onc News and JournalsTweet-
The dual BCL-2 and BCL-XL inhibitor AZD4320 acts on-target and synergizes with MCL-1 inhibition in B-cell precursor ALL https://t.co/F6tNPlJDuG #lymphoidneoplasia https://t.co/qCL83Y4WWN
-
-
Mashup Score: 6Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies - 7 hour(s) ago
Key PointsTeclistamab provides clinically meaningful responses in patients with R/RMM with prior anti-BCMA treatment.The two treatment-emergent grade ≥3 to
Source: ashpublications.orgCategories: General Medicine News, Onc News and JournalsTweet-
The two treatment-emergent grade ≥3 toxicities most frequently reported in patients with prior exposure to anti-BCMA therapy were cytopenias and infections. https://t.co/xoDQo5QG6B #clinicaltrialsandobservations #immunobiologyandimmunotherapy #lymphoidneoplasia #multiplemyeloma https://t.co/HjzXI7AK5x
-
-
Mashup Score: 1Isatuximab Plus VRd Enhances MRD Negativity and Responses in Transplant-Ineligible NDMM - 7 hour(s) ago
The phase 3 IMROZ trial showed isatuximab plus VRd and Rd maintenance improved MRD negativity and responses versus VRd alone in transplant-ineligible newly diagnosed multiple myeloma.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet-
At #ASH24, the phase 3 IMROZ trial showed isatuximab + VRd and Rd maintenance improved MRD negativity and responses vs VRd alone in transplant-ineligible newly diagnosed multiple myeloma. #mmsm | @Myeloma_Doc @MDAndersonNews https://t.co/xL5N9idvkZ
-
-
Mashup Score: 1The OncoAlert Newsletter is NOW OUT Click to Register - 8 hour(s) ago
The OncoAlert Newsletter is now out for June 23-29, 2023
Source: www.OncoAlert360.comCategories: General Medicine News, Onc News and JournalsTweet-
RT @BenWestphalen: Out today 💥 The new @OncoAlert 🚨 #newsletter - if you don’t want to miss out: register at https://t.co/AxMKHsMAQC 🌐
-
-
Mashup Score: 13Lack of Mask Mandates Leaves Cancer Patients Feeling Unprotected - 8 hour(s) ago
A lack of mask mandates at cancer centers and elsewhere has left cancer patients feeling unsafe and abandoned by society.
Source: www.cancertherapyadvisor.comCategories: General Medicine News, Onc News and JournalsTweet-
RT @TogetherWeMask: “Lack of Mask Mandates Leaves Cancer Patients Feeling Unprotected” https://t.co/lC3Cq7tTwr— @vickyyyf documented #Cance…
-
-
Mashup Score: 6Acute myeloid leukemia management and research in 2025 - 8 hour(s) ago
The first 5 decades of research in acute myeloid leukemia (AML) were dominated by the cytarabine plus anthracyclines backbone, with advances in strategies including allogeneic hematopoietic stem cell…
Categories: General Medicine News, Onc News and JournalsTweet-
Acute myeloid leukemia therapy has come a long way since being dominated by cytarabine and anthracyclines. @DrHKantarjian et al review the frontline and later line therapies in AML & discuss important research directions in this review. https://t.co/Vys7JCVfZF @OncoAlert #ASH24 https://t.co/lZIWY7sOps
-
❓ What is the link between tumor features and CAR-T response in #MCL? 📝 A study presented at #ASH24 by Zachary Epstein-Peterson, MD (@WeillCornell) lends insight. ➡️ https://t.co/4nU2AoFmDF https://t.co/hvEWs8Zmfo